REMARKS

Favorable consideration is respectfully requested in view of the foregoing amendments and the following remarks.

The foregoing amendments are presented to place the application in compliance with the sequence rules under 37 CFR 1.821-1.825.

Applicants have submitted a Sequence Listing in both paper and computer readable form as required by 37 C.F.R. 1.821(c) and (e). Amendments directing its entry into the specification have also been incorporated herein. The content of the paper and computer readable copies are the same and no new matter has been added.

Additional amendments to the specification have also been effected to put the specification in better form under U.S. practice. Specifically, the specification headings have been amended in conformance with U.S. practice.

With regard to the indication that an executed Oath and Declaration of the Inventors has not yet been submitted, Applicants wish to note that an executed Oath and Declaration was submitted with the application papers when the application was filed on February 5, 2001. A copy of the submitted executed Declaration is enclosed herewith along with the Transmittal letter and Postcard receipt (both indicating the filing of the executed Declaration). Applicants respectfully request that the Patent Office review the application papers filed February 5, 2001 to ensure that the executed Declaration is present in the file.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made."

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Tadashi Fujii et al.

Lee Chem

Registration No. 40,949 Attorney for Applicants

LC/gtn Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 May 25, 2001